Oncoinvent ASAOSL:ONCIN +14.58%37 PB Ratio is 2.02 as of Jul. 12, 2026, which is 26% below its 10-year median of 2.73. GuruFocus rates OSL:ONCIN with a GF Score™ of 37/100 and a GF Value™ of kr973.15 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,231 Biotechnology companies, Oncoinvent ASA ranks better than 63.44% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-12), Oncoinvent ASA's share price is kr66.00. Oncoinvent ASA's Book Value per Share for the quarter that ended in Dec. 2025 was kr32.68. Hence, Oncoinvent ASA's PB Ratio of today is 2.02.
Warning Sign:
Oncoinvent ASA stock PB Ratio (=2.02) is close to 1-year high of 2.02.
The historical rank and industry rank for Oncoinvent ASA's PB Ratio or its related term are showing as below:
OSL:ONCIN'
s PB Ratio Range Over the Past 10 Years
Min: 0.09 Med: 2.73 Max: 12.77
Current: 2.02
During the past 11 years, Oncoinvent ASA's highest PB Ratio was 12.77. The lowest was 0.09. And the median was 2.73.
OSL:ONCIN's PB Ratio is ranked better than 63.44% of 1231
companies
in the Biotechnology industry
Industry Median: 2.93
vs OSL:ONCIN: 2.02
During the past 12 months, Oncoinvent ASA's average Book Value Per Share Growth Rate was -81.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -81.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -78.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -43.70% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncoinvent ASA was 67.40% per year. The lowest was -81.90% per year. And the median was -22.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oncoinvent ASA PB Ratio Related Terms
Oncoinvent ASA PB Ratio Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:ONCIN vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Oncoinvent ASA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Oncoinvent ASA's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oncoinvent ASA (OSL:ONCIN) has a PB Ratio of 2.02 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncoinvent ASA and its competitors. This is 26% below median its historical median of 2.73. Over the past decade, Oncoinvent ASA's PB Ratio has ranged from 0.09 to 12.77. According to the industry distribution chart, Oncoinvent ASA ranks #450 out of 1231 companies in the Biotechnology industry, placing it in the top 36.6%.
Is Oncoinvent ASA's PB Ratio too high?
Oncoinvent ASA's current PB Ratio of 2.02 is 26% below median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 12.77. The Biotechnology industry median PB Ratio is 2.93. Oncoinvent ASA's value of 2.02 is 31.1% below this industry median. Based on the distribution chart, Oncoinvent ASA ranks #450 out of 1231 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oncoinvent ASA has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #450 out of 1231 companies for PB Ratio. This puts Oncoinvent ASA in the upper half of its industry. The industry median PB Ratio is 2.93. Oncoinvent ASA's value of 2.02 is 31.1% below this benchmark. Historically, Oncoinvent ASA's own PB Ratio has ranged from 0.09 to 12.77 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 2.93, Oncoinvent ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncoinvent ASA's current PB Ratio of 2.02 is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current PB Ratio is 2.02, which is 26% below median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Based on GuruFocus' analysis, Oncoinvent ASA (OSL:ONCIN) is currently considered Possible Value Trap. The stock's GF Value™ is kr973.15, compared to a current price of kr66.00 — trading 93.2% below its estimated fair value. The current PB Ratio is 2.02, which is 26% below median its 10-year median of 2.73 and 31.1% below the Biotechnology industry median of 2.93. Oncoinvent ASA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oncoinvent ASA (OSL:ONCIN), the current PB Ratio is 2.02 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (OSL:ONCIN) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr66.00 is trading 93.2% below its estimated GF Value™ of kr973.15.
GuruFocus considers Oncoinvent ASA to be Possible Value Trap.
Key valuation signals for OSL:ONCIN:
PB Ratio: 2.02 (26% below median its 10-year median of 2.73)
GF Value™: kr973.15 vs. price of kr66.00 (93.2% below fair value)
Industry Position: 31.1% below the Biotechnology median (#450 of 1231)
No single metric tells the full story. See the OSL:ONCIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
37GF Score
Get the complete analysis for OSL:ONCIN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:ONCIN has been successfully added to your 
